Other languages Hansa Biopharma AB

Equities

HNSA

SE0002148817

Market Closed - Nasdaq Stockholm Other stock markets 11:29:43 2024-04-25 am EDT			5-day change	1st Jan Change
27.2 ^SEK	-2.44%		-6.40%	+3.82%

Apr. 18	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Apr. 18	Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 18
Hansa Biopharma Approves SEK372 Million Directed Share Issue	Apr. 12
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	Apr. 02
Hansa Biopharma Hires New CFO	Feb. 22
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 02
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 02
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	Jan. 06
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 06
Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation	Dec. 14
Hansa Biopharma Nomination Committee Formed	Dec. 13
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial	Dec. 07
Hansa Biopharma Expects Up to SEK85 Million Annual Savings from Workforce Reduction Plan	Dec. 05
Hansa Biopharma Plans Restructuring to Strengthen Long-Term Competitiveness and Advance Key Deliverables	Dec. 05
Sweden's Hansa Biopharma CFO to Depart in February 2024	Nov. 27
Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26
Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients	23-10-17
Hansa Biopharma Announces Results from an Extended Pooled Analysis Using Data from the 17-Hmedides-14 Study, an International Long-Term Follow-Up Study of Patients Who Have Received A Kidney Transplant Following Desensitization with Imlifidase, Showing Sustained Positive Outcomes Out to 5 Years in the Majority of Highly Sensitized Patients Who Received an Imlifidase-Enabled Kidney Transplant	23-10-17
Hansa Biopharma to Finalize Randomization in Late-stage Kidney Study by Mid-2024	23-10-12
Hansa Biopharma Provides Clinical Pipeline Update on Confides Trial	23-10-11
Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients	23-10-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hansa Biopharma AB

Equities

HNSA

SE0002148817

Other languages

Filters